All
Weeks of TIL Therapy ‘Buys Years’ to Next Melanoma Treatment, Expert Says
February 22nd 2024Treatment with Amtagvi, a TIL therapy recently approved for advanced melanoma, includes a three-week hospital stay upfront, but may lead to years of monitoring without more treatment needed, an expert explained.
FDA Approves Dosing Reduction of Tecvayli in Relapsed, Refractory Myeloma
February 21st 2024The Food and Drug Administration has approved a reduced dosing frequency of Tecvayli for patients with relapsed or refractory multiple myeloma who have achieved and maintained a complete response or better for at least six months.